|
1) Kjeldsen L, Johnsen AH, Sengeløv H, et al. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993; 268: 10425-32
|
|
|
|
2) Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997; 45: 17-23
|
|
|
|
|
3) Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active renal damage. Kidney Int. 2007; 71: 967-70
|
|
|
|
|
|
4) 森 潔, 向山政志, 中尾一和. 多彩な生命現象の背後に潜む共通の分子基盤としてのNgalを介する鉄代謝. 感染・炎症・免疫. 2007; 37: 158-61
|
|
|
|
|
5) 森 潔, 向山政志, 中尾一和. 多彩な生命現象に関わる鉄結合性小化合物シデロフォアの意義. 細胞工学. 2008; 27: 226-30
|
|
|
|
|
|
6) Yang J, Goetz D, Li JY, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002; 10: 1045-56
|
|
|
|
|
|
7) Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005; 115: 610-21
|
|
|
|
|
|
8) Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta. 2000; 1482: 9-24
|
|
|
|
|
|
9) Goetz DH, Holmes MA, Borregaard N, et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002; 10: 1033-43
|
|
|
|
|
|
10) Li JY, Ram G, Gast K, et al. Detection of intracellular iron by its regulatory effect. Am J Physiol Cell Physiol. 2004; 287: C1547-59
|
|
|
|
|
|
11) Barasch J, Mori K. Cell biology: iron thievery. Nature. 2004; 432: 811-3
|
|
|
|
|
|
12) Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004; 432: 917-21
|
|
|
|
|
|
13) Berger T, Togawa A, Duncan GS, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2006; 103: 1834-9
|
|
|
|
|
|
14) Martineau AR, Newton SM, Wilkinson KA, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest. 2007; 117: 1988-94
|
|
|
|
|
|
15) Hanai J, Mammoto T, Seth P, et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 2005; 280: 13641-7
|
|
|
|
|
|
16) Devireddy LR, Teodoro JG, Richard FA, et al. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science. 2001; 293: 829-34
|
|
|
|
|
|
17) Devireddy LR, Gazin C, Zhu X, et al. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005; 123: 1293-305
|
|
|
|
|
|
18) Lee S, Lee J, Kim S, et al. A dual role of lipocalin 2 in the apoptosis and deramification of activated microglia. J Immunol. 2007; 179: 3231-41
|
|
|
|
|
|
19) Mishra J, Mori K, Ma Q, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003; 14: 2534-43
|
|
|
|
|
|
20) Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365: 1231-8
|
|
|
|
|
|
21) Wagener G, Jan M, Kim M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006; 105: 485-91
|
|
|
|
|
|
22) Coca SG, Yalavarthy R, Concato J, et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008; 73: 1008-16
|
|
|
|
|
|
23) Nickolas TL, O'Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008; 148: 810-9
|
|
|
|
|
|
24) Cowland JB, Muta T, Borregaard N. IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol. 2006; 176: 5559-66
|
|
|
|
|
|
25) Ding H, He Y, Li K, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol. 2007; 123: 227-34
|
|
|
|
|
|
26) Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 2009; 75: 285-94
|
|
|
|
|
|
27) Kasahara M, Mori K, Satoh N, et al. Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients. Nephrol Dial Transplant. 2009; 24: 2608-9
|
|
|
|
|
|
28) Hvidberg V, Jacobsen C, Strong RK, et al. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005; 579: 773-7
|
|
|
|
|
|
29) Damman K, van Veldhuisen DJ, Navis G, et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008; 10: 997-1000
|
|
|
|
|
|
30) Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 337-44
|
|
|
|
|